<DOC>
	<DOCNO>NCT01410188</DOCNO>
	<brief_summary>This study safety , tolerability , pharmacokinetics ( measurement drug level blood ) , intraocular pressure lower effect OPA-6566 ophthalmic solution subject primary open-angle glaucoma ocular hypertension .</brief_summary>
	<brief_title>Safety/Efficacy Study : OPA-6566 Ophthalmic Solution Subjects With Primary Open-Angle Glaucoma Ocular Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>diagnosis bilateral primary openangle glaucoma diagnosis ocular hypertension define protocol form glaucoma primary openangle glaucoma either eye ocular condition define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>open-angle glaucoma</keyword>
	<keyword>glaucoma</keyword>
	<keyword>ocular hypertension</keyword>
	<keyword>intraocular pressure</keyword>
</DOC>